Cargando…
Insulin is necessary but not sufficient: changing the therapeutic paradigm in type 1 diabetes
Despite the clear evidence that type 1 diabetes (T1D) begins well before hyperglycemia is evident, there are no clinically available disease-modifying therapies for early-stage disease. However, following the exciting results of the Teplizumab Prevention Study, the first study to demonstrate that ov...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
F1000 Research Limited
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7400689/ https://www.ncbi.nlm.nih.gov/pubmed/32789003 http://dx.doi.org/10.12688/f1000research.21801.1 |